Skip to main content
Log in

Overview

Targeted Oncology is a pragmatic tool for all physicians and scientists committed to oncology and cancer research.

Recently, a better understanding of the genetics and biology of cancer have provided important clues to the pathology of the disease and to new therapeutic strategies. Innovative treatments, including small molecule inhibitors and biologicals targeting oncogenic pathways and immune checkpoints have emerged and are currently revolutionizing the way we treat cancer patients. Despite these breakthroughs, significant work remains in understanding these new compounds and identifying markers of treatment success.

Targeted Oncology focuses on Original Research Articles on both pre-clinical and clinical aspects of molecularly targeted agents, and on comprehensive narrative Review Articles discussing clinically established as well as emerging agents and pathways. The journal also publishes Systematic Reviews that use explicit, systematic methods as outlined by the PRISMA statement, and Adis Drug Reviews of the properties and place in therapy of both newer and established targeted drugs in oncology.

As a hybrid journal, Targeted Oncology does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

Targeted Oncology offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Editor-in-Chief
  • Martin Chopra
Impact factor
5.4 (2022)
5 year impact factor
4.8 (2022)
Submission to first decision (median)
4 days
Downloads
341,527 (2023)

Latest articles

Journal updates

  • Digital Features

    Targeted Oncology is able to host a range of digital features, with a number of options available to authors.

Journal information

Electronic ISSN
1776-260X
Print ISSN
1776-2596
Abstracted and indexed in
  1. BFI List
  2. Baidu
  3. CLOCKSS
  4. CNKI
  5. CNPIEC
  6. Dimensions
  7. EBSCO
  8. EMBASE
  9. Google Scholar
  10. INIS Atomindex
  11. Japanese Science and Technology Agency (JST)
  12. Medline
  13. Naver
  14. Norwegian Register for Scientific Journals and Series
  15. OCLC WorldCat Discovery Service
  16. Portico
  17. ProQuest
  18. Reaxys
  19. SCImago
  20. SCOPUS
  21. Science Citation Index Expanded (SCIE)
  22. Semantic Scholar
  23. TD Net Discovery Service
  24. UGC-CARE List (India)
  25. Wanfang
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG

Navigation